Incannex Healthcare INC

Incannex Healthcare has commenced participant screening for its DReAMzz Phase 2 study of IHL-42X, a potential treatment for obstructive sleep apnea, marking a significant step towards Phase III development.

Incannex Healthcare has been granted a U.S. patent for its IHL-42X obstructive sleep apnoea treatment, extending intellectual property protection through 2040.

Incannex Healthcare announced the receipt of A$6.0 million in R&D tax incentive refunds, with an additional A$5.1 million expected, bolstering its financial position without dilution.

Incannex Healthcare announces initiation of equity research coverage by Alliance Global Partners with a BUY rating and a US$18.00 price target.

Incannex Healthcare has officially commenced its DReAMzz clinical study for IHL-42X, a potential treatment for obstructive sleep apnea, marking a significant step in its late-stage development.

Incannex Healthcare Inc. has won the MedTech Breakthrough Award for Best New Technology Solution for Drug Development for its obstructive sleep apnea treatment candidate, IHL-42X.

Incannex Healthcare reports increased cash reserves and reduced R&D expenses for the quarter ended March 31, 2026, while continuing development of its drug candidates.

Incannex Healthcare reports increased cash reserves from financing activities, strategic shifts in R&D programs, and ongoing efforts to address a material weakness in internal controls for the quarter ended December 31, 2025.

Incannex Healthcare Inc. reported an increased net loss for Q1 2026 but significantly strengthened its cash position through recent financing activities.

Incannex Healthcare Inc. announces its financial results for the quarter ended March 31, 2025, highlighting advancements in its clinical-stage biopharmaceutical development programs despite ongoing losses.

Incannex Healthcare's Q2 2025 report reveals ongoing losses, efforts to secure funding, and adjustments to clinical trial strategies.

Incannex Healthcare's Q1 2025 report reveals a widened net loss and increased operating expenses, alongside new financing agreements to support ongoing clinical trials.

Incannex Healthcare Inc. reported a significant increase in net loss for fiscal year 2025, driven by financing activities, while advancing its lead drug candidates IHL-42X and PSX-001 through clinical trials.

Incannex Healthcare Inc. released its annual 10-K report, detailing its clinical-stage biopharmaceutical operations, financial status, and future strategies.

Incannex Healthcare Inc. Director Troy Valentine was granted 11.3 million restricted shares under the company's 2023 Equity Incentive Plan, vesting through 2027.

Incannex Healthcare Inc. Director Robert Clark was granted 1,686,956 shares of common stock under the company's 2023 Equity Incentive Plan.

Incannex Healthcare Inc. Director Peter Widdows was granted 1,686,956 shares of restricted stock under the company's 2023 Equity Incentive Plan.

Incannex Healthcare Inc.'s CFO, Treasurer, and Secretary, Joseph Swan, was granted 869,565 shares of restricted common stock under the company's 2023 Equity Incentive Plan.

Incannex Healthcare Inc. CEO and President Joel Latham was granted 22.6 million restricted shares under the company's 2023 Equity Incentive Plan.

Incannex Healthcare Inc. Director George Anastassov acquired 1,686,956 shares of common stock through a restricted stock grant, increasing his beneficial ownership.

Incannex Healthcare Inc. has adjourned its 2025 Annual Meeting of Stockholders to January 15, 2026, due to a lack of quorum caused by an administrative error.

Incannex Healthcare Inc. expects to adjourn its 2025 Annual Meeting due to an administrative error classifying the Auditor Ratification Proposal as non-routine, hindering broker discretionary voting.

Incannex Healthcare Inc. announces its Annual Meeting of Stockholders for December 18, 2025, to vote on director elections and auditor ratification.

Incannex Healthcare Inc. announced its 2025 Annual Meeting of Stockholders to be held on December 18, 2025, to elect directors and ratify its independent auditor.

Incannex Healthcare modifies agreements with warrant holders to allow for sales of common stock through an at-the-market (ATM) facility, with proceeds used to reduce warrant share amounts.

Incannex Healthcare is holding a special meeting to seek stockholder approval for several key proposals, including increasing authorized shares, a reverse stock split, and amendments to its equity incentive plan.

Incannex Healthcare is registering for resale up to 75.9 million shares of common stock by selling stockholders, including shares held, shares issuable upon exercise of pre-funded warrants, and shares issuable upon exercise of Series A warrants.

Incannex Healthcare has filed an amended S-1 registration statement to allow the resale of up to 61.4 million shares of common stock by existing shareholders.

Incannex Healthcare aims to raise capital to advance clinical programs and for general corporate purposes through a public offering of common stock, pre-funded warrants, and common warrants.

Incannex Healthcare Inc. plans to offer shares of common stock and warrants to raise capital for clinical programs and general corporate purposes.

L1 Capital Global Opportunities Master Fund, Ltd. has filed an amended Schedule 13G, reporting a 4.99% beneficial ownership stake in Incannex Healthcare Inc. as of March 31, 2025.

S.H.N. Financial Investments Ltd. has filed an amended Schedule 13G, indicating a reduction to zero beneficial ownership in Incannex Healthcare Inc.'s common stock.

S.H.N. Financial Investments Ltd. has reported a 7.00% beneficial ownership stake in Incannex Healthcare Inc., holding 1,929,015 shares of common stock as of March 10, 2025.

L1 Capital Global Opportunities Master Fund, Ltd. has filed a Schedule 13G, revealing a 7.00% beneficial ownership stake in Incannex Healthcare Inc.'s common stock.